{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:34:20Z","timestamp":1790487260296,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T00:00:00Z","timestamp":1622160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Helmholtz-Zentrum f\u00fcr Infektionsforschung GmbH (HZI)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The major pathogen found in the lungs of adult cystic fibrosis (CF) patients is <jats:italic>Pseudomonas aeruginosa<\/jats:italic>, which builds antibiotic-resistant biofilms. Pulmonary delivery of antibiotics by inhalation has already been proved advantageous in the clinic, but the development of novel anti-infective aerosol medicines is complex and could benefit from adequate in vitro test systems. This work describes the first in vitro model of human bronchial epithelial cells cultivated at the air\u2013liquid interface (ALI) and infected with <jats:italic>P. aeruginosa<\/jats:italic> biofilm and its application to demonstrate the safety and efficacy of aerosolized anti-infective nanocarriers. Such a model may facilitate the translation of novel therapeutic modalities into the clinic, reducing animal experiments and the associated problems of species differences.\u00a0A preformed biofilm of <jats:italic>P. aeruginosa<\/jats:italic> PAO1 was transferred to filter-grown monolayers of the human CF cell line (CFBE41o-) at ALI and additionally supplemented with human tracheobronchial mucus. This experimental protocol provides an appropriate time window to deposit aerosolized ciprofloxacin-loaded nanocarriers at the ALI. When applied 1\u00a0h post-infection, the nanocarriers eradicated all planktonic bacteria and reduced the biofilm fraction of the pathogen by log 6, while CFBE41o- viability and barrier properties were maintained.\u00a0The here described complex in vitro model approach may open new avenues for preclinical safety and efficacy testing of aerosol medicines against <jats:italic>P. aeruginosa<\/jats:italic> lung infection.\n<\/jats:p>\n                <jats:p><jats:bold>Graphical abstract<\/jats:bold><\/jats:p>","DOI":"10.1007\/s13346-021-01002-8","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T14:15:28Z","timestamp":1622211328000},"page":"1752-1765","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Testing of aerosolized ciprofloxacin nanocarriers on cystic fibrosis airway cells infected with P. aeruginosa biofilms"],"prefix":"10.1007","volume":"11","author":[{"given":"Jenny","family":"Juntke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xabier","family":"Murgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazende","family":"G\u00fcnday T\u00fcreli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akif Emre","family":"T\u00fcreli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea R.","family":"Thorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Schneider-Daum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2560-675X","authenticated-orcid":false,"given":"Cristiane","family":"de Souza Carvalho-Wodarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Michael","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,28]]},"reference":[{"key":"1002_CR1","unstructured":"Foundation CF. What is CF - About Cystic Fibrosis. https:\/\/www.cff.org\/What-is-CF\/About-Cystic-Fibrosis\/. Accessed 11 Oct\u00a02020."},{"issue":"181","key":"1002_CR2","first-page":"1471","volume":"12","author":"CL Haley","year":"2012","unstructured":"Haley CL, Colmer-Hamood JA, Hamood AN. Characterization of biofilm-like structures formed by Pseudomonas aeruginosa in a synthetic mucus medium. BMC Microbiol. 2012;12(181):1471\u20132180.","journal-title":"BMC Microbiol"},{"key":"1002_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jcf.2005.05.005","volume":"4","author":"H Heijerman","year":"2005","unstructured":"Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros. 2005;4:3\u20135. https:\/\/doi.org\/10.1016\/j.jcf.2005.05.005.","journal-title":"J Cyst Fibros"},{"issue":"2","key":"1002_CR4","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1128\/cmr.15.2.194-222.2002","volume":"15","author":"JB Lyczak","year":"2002","unstructured":"Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev. 2002;15(2):194\u2013222. https:\/\/doi.org\/10.1128\/cmr.15.2.194-222.2002.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"1002_CR5","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/jac\/dku357","volume":"70","author":"S Moreau-Marquis","year":"2015","unstructured":"Moreau-Marquis S, Coutermarsh B, Stanton BA. Combination of hypothiocyanite and lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells. J Antimicrob Chemother. 2015;70(1):160\u20136.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"1002_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1165\/rcmb.2008-0299OC","volume":"41","author":"S Moreau-Marquis","year":"2009","unstructured":"Moreau-Marquis S, O\u2019Toole GA, Stanton BA. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol. 2009;41(3):305\u201313.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1002_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/apm.12099","volume":"136","author":"T Bjarnsholt","year":"2013","unstructured":"Bjarnsholt T. The role of bacterial biofilms in chronic infections. APMIS Suppl. 2013;136:1\u201351. https:\/\/doi.org\/10.1111\/apm.12099.","journal-title":"APMIS Suppl"},{"issue":"2","key":"1002_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1128\/cmr.15.2.167-193.2002","volume":"15","author":"RM Donlan","year":"2002","unstructured":"Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167\u201393. https:\/\/doi.org\/10.1128\/cmr.15.2.167-193.2002.","journal-title":"Clin Microbiol Rev"},{"issue":"14","key":"1002_CR9","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1056\/NEJMcibr021776","volume":"347","author":"A Prince","year":"2002","unstructured":"Prince A. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med. 2002;347(14):1110\u20131.","journal-title":"N Engl J Med"},{"issue":"4","key":"1002_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ijantimicag.2009.12.011","volume":"35","author":"N H\u00f8iby","year":"2010","unstructured":"H\u00f8iby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322\u201332. https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.12.011.","journal-title":"Int J Antimicrob Agents"},{"issue":"5418","key":"1002_CR11","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.284.5418.1318","volume":"284","author":"JW Costerton","year":"1999","unstructured":"Costerton JW. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318\u201322. https:\/\/doi.org\/10.1126\/science.284.5418.1318.","journal-title":"Science"},{"issue":"6","key":"1002_CR12","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1021\/js950381s","volume":"85","author":"PG Bhat","year":"1996","unstructured":"Bhat PG, Flanagan DR, Donovan MD. Drug diffusion through cystic fibrotic mucus: steady-state permeation, rheologic properties, and glycoprotein morphology. J Pharm Sci. 1996;85(6):624\u201330.","journal-title":"J Pharm Sci"},{"issue":"9276","key":"1002_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(01)05321-1","volume":"358","author":"PS Stewart","year":"2001","unstructured":"Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358(9276):135\u20138.","journal-title":"Lancet"},{"issue":"1","key":"1002_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1128\/AAC.47.1.317-323.2003","volume":"47","author":"MC Walters 3rd","year":"2003","unstructured":"Walters MC 3rd, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother. 2003;47(1):317\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"1002_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pupt.2015.07.003","volume":"34","author":"S Di Gioia","year":"2015","unstructured":"Di Gioia S, Trapani A, Castellani S, Carbone A, Belgiovine G, Craparo EF, et al. Nanocomplexes for gene therapy of respiratory diseases: targeting and overcoming the mucus barrier. Pulm Pharmacol Ther. 2015;34:8\u201324.","journal-title":"Pulm Pharmacol Ther"},{"key":"1002_CR16","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jconrel.2014.03.055","volume":"190","author":"K Forier","year":"2014","unstructured":"Forier K, Raemdonck K, De Smedt SC, Demeester J, Coenye T, Braeckmans K. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J Control Release. 2014;190:607\u201323. https:\/\/doi.org\/10.1016\/j.jconrel.2014.03.055.","journal-title":"J Control Release"},{"issue":"5","key":"1002_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","volume":"8","author":"H Heijerman","year":"2009","unstructured":"Heijerman H, Westerman E, Conway S, Touw D, Doring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2009;8(5):295\u2013315.","journal-title":"J Cyst Fibros"},{"issue":"9\u201310","key":"1002_CR18","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.addr.2006.07.009","volume":"58","author":"G Scheuch","year":"2006","unstructured":"Scheuch G, Kohlhaeufl MJ, Brand P, Siekmeier R. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv Drug Deliv Rev. 2006;58(9\u201310):996\u20131008. https:\/\/doi.org\/10.1016\/j.addr.2006.07.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"1002_CR19","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.colsurfb.2014.02.032","volume":"116","author":"K Hadinoto","year":"2014","unstructured":"Hadinoto K, Cheow WS. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa. Colloids Surf B Biointerfaces. 2014;116:772\u201385.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1002_CR20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.colsurfb.2015.08.027","volume":"135","author":"I D'Angelo","year":"2015","unstructured":"D\u2019Angelo I, Casciaro B, Miro A, Quaglia F, Mangoni ML, Ungaro F. Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide. Colloids Surf B Biointerfaces. 2015;135:717\u201325.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"1002_CR21","doi-asserted-by":"publisher","unstructured":"Ho DK, Murgia X, De Rossi C, Christmann R, H\u00fcfner de Mello Martins AG, Koch M et al. Squalenyl hydrogen sulfate nanoparticles for simultaneous delivery of tobramycin and an alkylquinolone quorum sensing inhibitor enable the eradication of P.\u2005aeruginosa biofilm infections. Angew Chem Int Ed Engl. 2020;59(26):10292\u20136.\u00a0https:\/\/doi.org\/10.1002\/anie.202001407.","DOI":"10.1002\/anie.202001407"},{"key":"1002_CR22","doi-asserted-by":"crossref","unstructured":"Bayes HK, Ritchie N, Irvine S, Evans TJ. A murine model of early Pseudomonas aeruginosa lung disease with transition to chronic infection. Sci Rep. 2016;6(35838).","DOI":"10.1038\/srep35838"},{"key":"1002_CR23","doi-asserted-by":"crossref","unstructured":"Baldan R, Cigana C, Testa F, Bianconi I, De Simone M, Pellin D et al. Adaptation of Pseudomonas aeruginosa in Cystic Fibrosis airways influences virulence of Staphylococcus aureus in vitro and murine models of co-infection. PLoS One. 2014;9(3).","DOI":"10.1371\/journal.pone.0089614"},{"issue":"8","key":"1002_CR24","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1128\/AAC.46.8.2575-2581.2002","volume":"46","author":"IA Bakker-Woudenberg","year":"2002","unstructured":"Bakker-Woudenberg IA, ten Kate MT, Guo L, Working P, Mouton JW. Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2002;46(8):2575\u201381.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1002_CR25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3390\/pathogens2020288","volume":"2","author":"D Lebeaux","year":"2013","unstructured":"Lebeaux D, Chauhan A, Rendueles O, Beloin C. From in vitro to in vivo models of bacterial biofilm-related infections. Pathogens. 2013;2(2):288\u2013356. https:\/\/doi.org\/10.3390\/pathogens2020288.","journal-title":"Pathogens"},{"key":"1002_CR26","unstructured":"Russell WMS, Burch RL. The principles of humane experimental technique. Methuen; 1959."},{"issue":"6","key":"1002_CR27","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1128\/JCM.37.6.1771-1776.1999","volume":"37","author":"H Ceri","year":"1999","unstructured":"Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol. 1999;37(6):1771\u20136.","journal-title":"J Clin Microbiol"},{"key":"1002_CR28","first-page":"22","volume":"22","author":"W Elkhatib","year":"2014","unstructured":"Elkhatib W, Noreddin A. Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. Microb Drug Resist. 2014;22:22.","journal-title":"Microb Drug Resist"},{"key":"1002_CR29","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.freeradbiomed.2014.08.011","volume":"77","author":"AC Zemke","year":"2014","unstructured":"Zemke AC, Shiva S, Burns JL, Moskowitz SM, Pilewski JM, Gladwin MT, et al. Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cells. Free Radic Biol Med. 2014;77:307\u201316.","journal-title":"Free Radic Biol Med"},{"key":"1002_CR30","doi-asserted-by":"publisher","unstructured":"Moreau-Marquis S, Redelman CV, Stanton BA, Anderson GG. Co-culture models of Pseudomonas aeruginosa biofilms grown on live human airway cells. Journal of Visualized Experiments. 2010(44). https:\/\/doi.org\/10.3791\/2186.","DOI":"10.3791\/2186"},{"issue":"4","key":"1002_CR31","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1128\/iai.01373-07","volume":"76","author":"GG Anderson","year":"2008","unstructured":"Anderson GG, Moreau-Marquis S, Stanton BA, O\u2019Toole GA. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa Biofilms on Cystic Fibrosis-derived airway epithelial cells. Infect Immun. 2008;76(4):1423\u201333. https:\/\/doi.org\/10.1128\/iai.01373-07.","journal-title":"Infect Immun"},{"issue":"10","key":"1002_CR32","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1093\/jac\/dky241","volume":"73","author":"L M\u00fcller","year":"2018","unstructured":"M\u00fcller L, Murgia X, Siebenb\u00fcrger L, B\u00f6rger C, Schwarzkopf K, Sewald K, et al. Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin. J Antimicrob Chemother. 2018;73(10):2762\u20139. https:\/\/doi.org\/10.1093\/jac\/dky241.","journal-title":"J Antimicrob Chemother"},{"issue":"1\u20132","key":"1002_CR33","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijpharm.2016.10.025","volume":"515","author":"N Gunday Tureli","year":"2016","unstructured":"Gunday Tureli N, Tureli AE, Schneider M. Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: Design of experiments approach. Int J Pharm. 2016;515(1\u20132):343\u201351.","journal-title":"Int J Pharm"},{"issue":"2","key":"1002_CR34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.ijpharm.2016.08.004","volume":"511","author":"N Gunday Tureli","year":"2016","unstructured":"Gunday Tureli N, Tureli AE, Schneider M. Counter-ion complexes for enhanced drug loading in nanocarriers: proof-of-concept and beyond. Int J Pharm. 2016;511(2):994\u20131001.","journal-title":"Int J Pharm"},{"key":"1002_CR35","doi-asserted-by":"publisher","unstructured":"G\u00fcnday T\u00fcreli N, Torge A, Juntke J, Schwarz BC, Schneider-Daum N, T\u00fcreli AE et al. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. Eur J Pharm Biopharm. 2017;117:363\u201371.\u00a0https:\/\/doi.org\/10.1016\/j.ejpb.2017.04.032.","DOI":"10.1016\/j.ejpb.2017.04.032"},{"key":"1002_CR36","doi-asserted-by":"publisher","unstructured":"Horstmann JC, Thorn CR, Carius P, Graef F, Murgia X, De Souza Carvalho Wodarz C et al. A custom-made device for reproducibly depositing pre-metered doses of nebulized drugs on pulmonary cells in vitro. Frontiers in Bioengineering and Biotechnology. 2021.\u00a0https:\/\/doi.org\/10.3389\/fbioe.2021.643491.","DOI":"10.3389\/fbioe.2021.643491"},{"key":"1002_CR37","doi-asserted-by":"publisher","unstructured":"Bruscia E, Sangiuolo F, Sinibaldi P, Goncz KK, Novelli G, DC. G. Isolation of CF cell lines corrected at DeltaF508-CFTR locus by SFHR-mediated targeting. Gene Ther. 2002 Jun;9(11):683\u20135. https:\/\/doi.org\/10.1038\/sj\/gt\/3301741.","DOI":"10.1038\/sj\/gt\/3301741"},{"issue":"1","key":"1002_CR38","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1165\/ajrcmb.10.1.7507342","volume":"10","author":"AL Cozens","year":"1994","unstructured":"Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, et al. CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. Am J Respir Cell Mol Biol. 1994;10(1):38\u201347.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"1002_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1152\/ajplung.00391.2007.-Enhanced","volume":"295","author":"S Moreau-Marquis","year":"2008","unstructured":"Moreau-Marquis S, Bomberger JM, Anderson GG, Swiatecka-Urban A, Ye S, O\u2019Toole GA, et al. The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol. 2008;295(1):25\u201337. https:\/\/doi.org\/10.1152\/ajplung.00391.2007.-Enhanced.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"1002_CR40","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00441-005-0062-7","volume":"323","author":"C Ehrhardt","year":"2005","unstructured":"Ehrhardt C, Collnot E-M, Baldes C, Becker U, Laue M, Kim K-J, et al. Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o. Cell Tissue Res. 2005;323(3):405\u201315. https:\/\/doi.org\/10.1007\/s00441-005-0062-7.","journal-title":"Cell Tissue Res"},{"key":"1002_CR41","doi-asserted-by":"crossref","unstructured":"Murgia X, Yasara H, Carvalho-Wodarz C, Loretz B, Gordon S, Schwarzkopf K et al. Modelling the bronchial barrier in pulmonary drug delivery: a human bronchial epithelial cell line supplemented with human tracheal mucus. Eur J Phar Biopharm. 2016.","DOI":"10.1016\/j.ejpb.2017.03.020"},{"key":"1002_CR42","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev.mi.40.100186.000455","volume":"40","author":"BW Holloway","year":"1986","unstructured":"Holloway BW, Morgan AF. Genome organization in Pseudomonas. Annu Rev Microbiol. 1986;40:79\u2013105.","journal-title":"Annu Rev Microbiol"},{"issue":"2","key":"1002_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.mimet.2007.11.010","volume":"72","author":"E Peeters","year":"2008","unstructured":"Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods. 2008;72(2):157\u201365. https:\/\/doi.org\/10.1016\/j.mimet.2007.11.010.","journal-title":"J Microbiol Methods"},{"issue":"2","key":"1002_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s0167-7012(00)00122-6","volume":"40","author":"S Stepanovic","year":"2000","unstructured":"Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods. 2000;40(2):175\u20139. https:\/\/doi.org\/10.1016\/s0167-7012(00)00122-6.","journal-title":"J Microbiol Methods"},{"issue":"5","key":"1002_CR45","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1023\/A:1023441804464","volume":"20","author":"J Fiegel","year":"2003","unstructured":"Fiegel J, Ehrhardt C, Schaefer UF, Lehr CM, Hanes J. Large porous particle impingement on lung epithelial cell monolayers\u2013toward improved particle characterization in the lung. Pharm Res. 2003;20(5):788\u201396.","journal-title":"Pharm Res"},{"key":"1002_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev.micro.54.1.49","volume":"54","author":"G O'Toole","year":"2000","unstructured":"O\u2019Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol. 2000;54:49\u201379.","journal-title":"Annu Rev Microbiol"},{"key":"1002_CR47","doi-asserted-by":"publisher","unstructured":"Kostakioti M, Hadjifrangiskou M, Hultgren SJ. Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harbor Perspectives in Medicine. 2013;3(4):a010306-a.\u00a0https:\/\/doi.org\/10.1101\/cshperspect.a010306.","DOI":"10.1101\/cshperspect.a010306"},{"issue":"6","key":"1002_CR48","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1046\/j.1365-2958.2003.03525.x","volume":"48","author":"M Klausen","year":"2003","unstructured":"Klausen M, Heydorn A, Ragas P, Lambertsen L, Aaes-J\u00f8rgensen A, Molin S, et al. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol Microbiol. 2003;48(6):1511\u201324. https:\/\/doi.org\/10.1046\/j.1365-2958.2003.03525.x.","journal-title":"Mol Microbiol"},{"issue":"7","key":"1002_CR49","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1039\/c0sm01467b","volume":"7","author":"O Lieleg","year":"2011","unstructured":"Lieleg O, Caldara M, Baumg\u00e4rtel R, Ribbeck K. Mechanical robustness of Pseudomonas aeruginosa biofilms. Soft Matter. 2011;7(7):3307\u201314. https:\/\/doi.org\/10.1039\/c0sm01467b.","journal-title":"Soft Matter"},{"issue":"6","key":"1002_CR50","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ppul.21011","volume":"44","author":"T Bjarnsholt","year":"2009","unstructured":"Bjarnsholt T, Jensen P\u00d8, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol. 2009;44(6):547\u201358. https:\/\/doi.org\/10.1002\/ppul.21011.","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"1002_CR51","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.tim.2013.06.002","volume":"21","author":"T Bjarnsholt","year":"2013","unstructured":"Bjarnsholt T, Alhede M, Alhede M, Eickhardt-S\u00f8rensen SR, Moser C, K\u00fchl M, et al. The in vivo biofilm. Trends Microbiol. 2013;21(9):466\u201374. https:\/\/doi.org\/10.1016\/j.tim.2013.06.002.","journal-title":"Trends Microbiol"},{"issue":"24","key":"1002_CR52","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/j.cub.2012.10.028","volume":"22","author":"M Caldara","year":"2012","unstructured":"Caldara M, Friedlander RS, Kavanaugh NL, Aizenberg J, Foster KR, Ribbeck K. Mucin biopolymers prevent bacterial aggregation by retaining cells in the free-swimming state. Curr Biol. 2012;22(24):2325\u201330. https:\/\/doi.org\/10.1016\/j.cub.2012.10.028.","journal-title":"Curr Biol"},{"issue":"2","key":"1002_CR53","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1128\/iai.62.2.596-605.1994","volume":"62","author":"E Mahenthiralingam","year":"1994","unstructured":"Mahenthiralingam E, Campbell ME, Speert DP. Nonmotility and phagocytic resistance of Pseudomonas aeruginosa isolates from chronically colonized patients with cystic fibrosis. Infect Immun. 1994;62(2):596\u2013605. https:\/\/doi.org\/10.1128\/iai.62.2.596-605.1994.","journal-title":"Infect Immun"},{"issue":"11","key":"1002_CR54","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1164\/rccm.200408-1044SO","volume":"171","author":"RT Sadikot","year":"2005","unstructured":"Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2005;171(11):1209\u201323. https:\/\/doi.org\/10.1164\/rccm.200408-1044SO.","journal-title":"Am J Respir Crit Care Med"},{"issue":"13","key":"1002_CR55","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s40265-020-01359-z","volume":"80","author":"M Bassetti","year":"2020","unstructured":"Bassetti M, Vena A, Russo A, Peghin M. Inhaled liposomal antimicrobial delivery in lung infections. Drugs. 2020;80(13):1309\u201318. https:\/\/doi.org\/10.1007\/s40265-020-01359-z.","journal-title":"Drugs"},{"key":"1002_CR56","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.2147\/dddt.S168014","volume":"12","author":"S Chorepsima","year":"2018","unstructured":"Chorepsima S, Kechagias KS, Kalimeris G, Triarides NA, Falagas ME. Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis. Drug Des Devel Ther. 2018;12:4059\u201366. https:\/\/doi.org\/10.2147\/dddt.S168014.","journal-title":"Drug Des Devel Ther"},{"key":"1002_CR57","unstructured":"Bayer. Bayer Annual Report 2017 \u2013 Augmented Version\u00a02018."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01002-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-021-01002-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-021-01002-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T20:05:04Z","timestamp":1624737904000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-021-01002-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,28]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1007\/s13346-021-01002-8","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,28]]},"assertion":[{"value":"11 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}